Lundbeck "buy"

12/06/05 - ING Financial Markets

LONDON, December 6 (newratings.com) - Analysts at ING Financial Markets maintain their "buy" rating on Lundbeck (LDB). The 12-month target price is set to DKK150.

In a research note published this morning, the analysts mention that the headline data for the company’s bifeprunox drug is expected to be released in 4Q05. According to the analysts, a decision regarding the lawsuit between Lundbeck/Forest and Ivax over the Lexapro patent is unlikely before late-2006.